Arbor launches with $15.6 million, new CRISPR enzyme
Arbor Biotechnologies Inc. (Cambridge, Mass.) emerged from stealth mode on Thursday with a study detailing the discovery of a new CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and a $15.6 million series A round that closed last June. Investors included Arch Venture Partners, Faridan, Alexandria Real Estate Equities and private investors.
Launched in 2016 by co-founders including CRISPR pioneer Feng Zhang and Illumina Inc. (NASDAQ:ILMN) and Quanterix Corp. (NASDAQ:QTRX) co-founder David Walt, Arbor has a genome screening platform to identify new natural proteins and peptides with potential medical, agricultural and industrial applications. The platform combines a set of AI, genome sequencing, gene synthesis and high-throughput screening technologies. ...